← back to search

Xiaoyuan Qiao

Shanxi Medical University · CN
Area of research
Pulmonary and Respiratory Medicine · Neurology
Research interest
Research topics from publications: Community physicians’ knowledge of secondary prevention after ischemic stroke: a questionnaire survey in Shanxi Province, China; Related factors based on non-targeted metabolomics methods in minor ischaemic stroke; Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study; Integrating multi-omics techniques and in vitro experiments reveals that GLRX3 regulates the immune microenvironment and promotes hepatocellular carcinoma cell proliferation and invasion through iron metabolism pathways. Representative work: BACKGROUND: This cross-sectional, questionnaire-based survey, conducted in Shanxi Province, China, evaluated the knowledge of community physicians of secondary prevention of ischemic stroke and transient ischemic attacks (TIAs). METHODS: A total of 1910 physicians practicing at 832 community-based clinics, hospitals and other care centers in 11 prefectures of Shanxi Province completed the questionnaires between 1 July and 30 September 2013. RESULTS: Over 90 % of participants were aware of the most common risk factors for stroke, but lifestyle-related factors were seen as of low or medium importance for secondary prevention. Only about 50 % of physicians were aware of the existence of commonl Objective: This study aimed to identify potential biomarkers associated with the occurrence of minor ischaemic stroke. Methods: Four hundred patients hospitalized with minor ischaemic stroke were enrolled in the department of neurological internal medicine in Taiyuan Central Hospital, and 210 healthy subjects examined at the Taiyuan Central Hospital Medical Center during the same period were selected. We collected information on the general demographic characteristics and fasting blood samples of the subjects. We then used untargeted metabolomic assay to measure blood glucose, blood lipids, homocysteine, and high-sensitivity C-reactive protein. Results: There were statistically significant d
h-index
citations
0
works
0
NIH funding
primary concept
email

Recent publications

Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study.
Journal of Clinical Oncology 2024cited by 6position: middledoi
Integrating multi-omics techniques and in vitro experiments reveals that GLRX3 regulates the immune microenvironment and promotes hepatocellular carcinoma cell proliferation and invasion through iron metabolism pathways
Frontiers in Immunology 2024cited by 4position: lastdoi
Related factors based on non-targeted metabolomics methods in minor ischaemic stroke
Frontiers in Endocrinology 2022cited by 15position: middledoi
Community physicians’ knowledge of secondary prevention after ischemic stroke: a questionnaire survey in Shanxi Province, China
BMC Medical Education 2015cited by 19position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ling Ding · Shenyang Pharmaceutical University2 papers (2015–2022)Xin Wang · University of Kentucky1 papers (2024–2024)Min Wang · Academy of Military Medical Sciences1 papers (2022–2022)Zhibin Li · Guangzhou University of Chinese Medicine1 papers (2024–2024)Yang Zhang · Nanchang University1 papers (2024–2024)Jintao Wang · Nanchang University1 papers (2022–2022)Yuan Chen · Sinopec (China)1 papers (2024–2024)Yu Cui · Taiyuan University of Technology1 papers (2024–2024)Hong Liu · Prevention Institute1 papers (2022–2022)Chen Chen · Chinese Center For Disease Control and Prevention1 papers (2015–2015)Chen Chen · Weifang Medical University1 papers (2022–2022)Xi Zhang · The University of Texas Southwestern Medical Center1 papers (2024–2024)Lixia Bai · Shanxi Medical University1 papers (2015–2015)Han Xue-bing · Shanxi Medical University1 papers (2024–2024)Jianyong Guo · Shanxi Medical University1 papers (2022–2022)Shuhe Zhao · Shanxi Medical University1 papers (2022–2022)Ling Wu · Shanxi Medical University1 papers (2024–2024)Sujun Han · Chinese Academy of Medical Sciences & Peking Union Medical College1 papers (2024–2024)Mingshuai Wang · Chang'an University1 papers (2024–2024)Linjun Hu · Sun Yat-sen University Cancer Center1 papers (2024–2024)